The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

18FDG     (2S,3R,4S,5S,6R)-3-fluoro-6...

Synonyms: SureCN5674906, CHEBI:49132, AC1L9HML, ZINC03809846, LS-186650, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Fludeoxyglucose F 18


Psychiatry related information on Fludeoxyglucose F 18


High impact information on Fludeoxyglucose F 18


Chemical compound and disease context of Fludeoxyglucose F 18


Biological context of Fludeoxyglucose F 18

  • Measurements of the rate constants for transport and phosphorylation process indicate that their change with aging had no major effect on the measurement of lCMRGlu by the 18FDG method [17].
  • Therefore, PET using L-[1-11C]tyrosine and 18FDG is suitable to monitor kinetics of tumor growth and tumor regression after radiotherapy [18].
  • In 41 patients with progressive supranuclear palsy (PSP) that was diagnosed on the basis of eight clinical criteria (25 patients with all eight criteria [probable PSP] and 16 with six or seven criteria [possible PSP]), we studied cerebral energy metabolism by using positron emission tomography and the fludeoxyglucose F 18 or the oxygen 15 method [19].
  • Moreover, consistent with the 18FDG uptake data, injured piglets had moderate to severe injury on lung histology whereas control piglets had only slight and focal histologic changes [20].
  • The clearance rate of 18FDG, defined as the retention ratio of 18FDG activity to the initially deposited 18FDG at 60 and 120 min after inhalation, in the trachea, large bronchi or peripheral lung fields measured by tomographic scan showed a wider variation in COPD patients than in normals [21].

Anatomical context of Fludeoxyglucose F 18


Associations of Fludeoxyglucose F 18 with other chemical compounds

  • We examined differences between SPECT and PET technologies and between 18FDG and thallium tracers to determine whether 18FDG SPECT could be adopted for assessment of myocardial viability [12].
  • Quantification was restricted by incomplete understanding of tracer behavior in diseased brain, but relative local distributions of 18FDG and 13NH3 trapping qualitatively reflected the increases and decreases as well as coupling and uncoupling expected for local alterations in glucose utilization and perfusion in stroke [4].
  • Seventeen patients with partial epilepsy had electroencephalographic (EEG) monitoring concurrent with cerebral positron emission computed tomography (PECT) after 18F-fluorodeoxyglucose (18FDG) and 13N-ammonia (13NH3) were given intravenously as indicators of local cerebral glucose utilization (LCMRglc) and relative perfusion, respectively [26].
  • Using positron emission tomography with fluorodeoxyglucose (18FDG or FDG), we compared the effects of zolpidem (10 mg), an imidazopyridine hypnotic, which is relatively selective for the BZ1 or omega receptor and placebo on cerebral glucose metabolism during the first non-REM sleep period of 12 young normal volunteers [27].
  • Hexokinase catalyzes the phosphorylation of glucose, as well as 18FDG and 2-deoxyglucose (2DG), thereby "trapping" these slowly metabolized analogues intracellularly [28].

Gene context of Fludeoxyglucose F 18


Analytical, diagnostic and therapeutic context of Fludeoxyglucose F 18

  • Maturational changes in cerebral function in infants determined by 18FDG positron emission tomography [33].
  • Combined SPECT perfusion and PET fludeoxyglucose F 18 metabolic imaging is emerging as a method for determining appropriateness of revascularization [34].
  • However, of the 78 segments confirmed to be nonviable by 18FDG PET, 57 (73%) were nonviable by 18FDG SPECT (P<.001) [12].
  • CONCLUSION: 18FDG PET is superior to bone scintigraphy in the detection of osteolytic breast cancer metastases, which led to a poorer prognosis [3].
  • In 12 of 15 patients who had unilateral or focal electrical abnormalities, interictal 18FDG scan patterns clearly showed localized regions of decreased (14 to 58%) LCMRglc that correlated anatomically with the eventual EEG localization [26].


  1. Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer. Lewis, P., Griffin, S., Marsden, P., Gee, T., Nunan, T., Malsey, M., Dussek, J. Lancet (1994) [Pubmed]
  2. A new strategy for the assessment of viable myocardium and regional myocardial blood flow using 15O-water and dynamic positron emission tomography. Yamamoto, Y., de Silva, R., Rhodes, C.G., Araujo, L.I., Iida, H., Rechavia, E., Nihoyannopoulos, P., Hackett, D., Galassi, A.R., Taylor, C.J. Circulation (1992) [Pubmed]
  3. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. Cook, G.J., Houston, S., Rubens, R., Maisey, M.N., Fogelman, I. J. Clin. Oncol. (1998) [Pubmed]
  4. Effects of stroke on local cerebral metabolism and perfusion: mapping by emission computed tomography of 18FDG and 13NH3. Kuhl, D.E., Phelps, M.E., Kowell, A.P., Metter, E.J., Selin, C., Winter, J. Ann. Neurol. (1980) [Pubmed]
  5. Temporal and hippocampal metabolic rate during an olfactory memory task assessed by positron emission tomography in patients with dementia of the Alzheimer type and controls. Preliminary studies. Buchsbaum, M.S., Kesslak, J.P., Lynch, G., Chui, H., Wu, J., Sicotte, N., Hazlett, E., Teng, E., Cotman, C.W. Arch. Gen. Psychiatry (1991) [Pubmed]
  6. Cerebral glucose metabolic patterns in Alzheimer's disease. Effect of gender and age at dementia onset. Small, G.W., Kuhl, D.E., Riege, W.H., Fujikawa, D.G., Ashford, J.W., Metter, E.J., Mazziotta, J.C. Arch. Gen. Psychiatry (1989) [Pubmed]
  7. Dorsal striatal size, shape, and metabolic rate in never-medicated and previously medicated schizophrenics performing a verbal learning task. Shihabuddin, L., Buchsbaum, M.S., Hazlett, E.A., Haznedar, M.M., Harvey, P.D., Newman, A., Schnur, D.B., Spiegel-Cohen, J., Wei, T., Machac, J., Knesaurek, K., Vallabhajosula, S., Biren, M.A., Ciaravolo, T.M., Luu-Hsia, C. Arch. Gen. Psychiatry (1998) [Pubmed]
  8. Positron emission tomography measurement of cerebral metabolic correlates of yohimbine administration in combat-related posttraumatic stress disorder. Bremner, J.D., Innis, R.B., Ng, C.K., Staib, L.H., Salomon, R.M., Bronen, R.A., Duncan, J., Southwick, S.M., Krystal, J.H., Rich, D., Zubal, G., Dey, H., Soufer, R., Charney, D.S. Arch. Gen. Psychiatry (1997) [Pubmed]
  9. Cerebral metabolism and atrophy in Huntington's disease determined by 18FDG and computed tomographic scan. Kuhl, D.E., Phelps, M.E., Markham, C.H., Metter, E.J., Riege, W.H., Winter, J. Ann. Neurol. (1982) [Pubmed]
  10. High levels of dopamine D2 receptors in unaffected members of alcoholic families: possible protective factors. Volkow, N.D., Wang, G.J., Begleiter, H., Porjesz, B., Fowler, J.S., Telang, F., Wong, C., Ma, Y., Logan, J., Goldstein, R., Alexoff, D., Thanos, P.K. Arch. Gen. Psychiatry (2006) [Pubmed]
  11. Positron emission tomography of regional brain metabolic responses to a serotonergic challenge and lethality of suicide attempts in major depression. Oquendo, M.A., Placidi, G.P., Malone, K.M., Campbell, C., Keilp, J., Brodsky, B., Kegeles, L.S., Cooper, T.B., Parsey, R.V., van Heertum, R.L., Mann, J.J. Arch. Gen. Psychiatry (2003) [Pubmed]
  12. [18F]fluorodeoxyglucose single photon emission computed tomography: can it replace PET and thallium SPECT for the assessment of myocardial viability? Srinivasan, G., Kitsiou, A.N., Bacharach, S.L., Bartlett, M.L., Miller-Davis, C., Dilsizian, V. Circulation (1998) [Pubmed]
  13. The effect of nifedipine on myocardial perfusion and metabolism in systemic sclerosis. A positron emission tomographic study. Duboc, D., Kahan, A., Maziere, B., Loc'h, C., Crouzel, C., Menkès, C.J., Amor, B., Strauch, G., Guérin, F., Syrota, A. Arthritis Rheum. (1991) [Pubmed]
  14. Quantifying pulmonary inflammation in cystic fibrosis with positron emission tomography. Chen, D.L., Ferkol, T.W., Mintun, M.A., Pittman, J.E., Rosenbluth, D.B., Schuster, D.P. Am. J. Respir. Crit. Care Med. (2006) [Pubmed]
  15. Functional effects of striatal dysfunction in Parkinson disease. Holthoff-Detto, V.A., Kessler, J., Herholz, K., Bönner, H., Pietrzyk, U., Würker, M., Ghaemi, M., Wienhard, K., Wagner, R., Heiss, W.D. Arch. Neurol. (1997) [Pubmed]
  16. Preoperative FDG-PET for axillary metastases in patients with breast cancer. Chung, A., Liou, D., Karlan, S., Waxman, A., Fujimoto, K., Hagiike, M., Phillips, E.H. Archives of surgery (Chicago, Ill. : 1960) (2006) [Pubmed]
  17. The effect of normal aging on patterns of local cerebral glucose utilization. Kuhl, D.E., Metter, E.J., Riege, W.H., Hawkins, R.A. Ann. Neurol. (1984) [Pubmed]
  18. Radiation-induced inhibition of tumor growth as monitored by PET using L-[1-11C]tyrosine and fluorine-18-fluorodeoxyglucose. Daemen, B.J., Elsinga, P.H., Paans, A.M., Wieringa, A.R., Konings, A.W., Vaalburg, W. J. Nucl. Med. (1992) [Pubmed]
  19. Positron emission tomography study in progressive supranuclear palsy. Brain hypometabolic pattern and clinicometabolic correlations. Blin, J., Baron, J.C., Dubois, B., Pillon, B., Cambon, H., Cambier, J., Agid, Y. Arch. Neurol. (1990) [Pubmed]
  20. [18F]fluorodeoxyglucose uptake in neonatal acute lung injury measured by positron emission tomography. Kirpalani, H., Abubakar, K., Nahmias, C., deSa, D., Coates, G., Schmidt, B. Pediatr. Res. (1997) [Pubmed]
  21. Deposition and clearance of inhaled 18FDG powder in patients with chronic obstructive pulmonary disease. Yanai, M., Hatazawa, J., Ojima, F., Sasaki, H., Itoh, M., Ido, T. Eur. Respir. J. (1998) [Pubmed]
  22. Issues in the in vivo measurement of glucose metabolism of human central nervous system tumors. Di Chiro, G., Brooks, R.A., Patronas, N.J., Bairamian, D., Kornblith, P.L., Smith, B.H., Mansi, L., Barker, J. Ann. Neurol. (1984) [Pubmed]
  23. Fludeoxyglucose positron emission tomography in the diagnosis of giant cell arteritis. Turlakow, A., Yeung, H.W., Pui, J., Macapinlac, H., Liebovitz, E., Rusch, V., Goy, A., Larson, S.M. Arch. Intern. Med. (2001) [Pubmed]
  24. Use of 18FDG-pet to discriminate between infection and rejection in lung transplant recipients. Jones, H.A., Donovan, T., Goddard, M.J., McNeil, K., Atkinson, C., Clark, J.C., White, J.F., Chilvers, E.R. Transplantation (2004) [Pubmed]
  25. Pattern of interictal hypometabolism in PET scans with fludeoxyglucose F 18 reflects prior seizure types in patients with mesial temporal lobe seizures. Savic, I., Altshuler, L., Baxter, L., Engel, J. Arch. Neurol. (1997) [Pubmed]
  26. Epileptic patterns of local cerebral metabolism and perfusion in humans determined by emission computed tomography of 18FDG and 13NH3. Kuhl, D.E., Engel, J., Phelps, M.E., Selin, C. Ann. Neurol. (1980) [Pubmed]
  27. Effects of zolpidem on local cerebral glucose metabolism during non-REM sleep in normal volunteers: a positron emission tomography study. Gillin, J.C., Buchsbaum, M.S., Valladares-Neto, D.C., Hong, C.C., Hazlett, E., Langer, S.Z., Wu, J. Neuropsychopharmacology (1996) [Pubmed]
  28. Regulation of hexokinase in cultured gliomas. Graham, J.F., Cummins, C.J., Smith, B.H., Kornblith, P.L. Neurosurgery (1985) [Pubmed]
  29. Role of glycolysis in the energy production for the non-mechanical myocardial work in isolated pig hearts. Bendjelid, K., Canet, E., Rayan, E., Casali, C., Revel, D., Janier, M. Current medical research and opinion. (2003) [Pubmed]
  30. Human pathologic correlation with PET in ischemic and nonischemic cardiomyopathy. Berry, J.J., Hoffman, J.M., Steenbergen, C., Baker, J.A., Floyd, C., Van Trigt, P., Hanson, M.W., Coleman, R.E. J. Nucl. Med. (1993) [Pubmed]
  31. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. Feine, U., Lietzenmayer, R., Hanke, J.P., Held, J., Wöhrle, H., Müller-Schauenburg, W. J. Nucl. Med. (1996) [Pubmed]
  32. Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emission tomographic study. Mega, M.S., Dinov, I.D., Porter, V., Chow, G., Reback, E., Davoodi, P., O'Connor, S.M., Carter, M.F., Amezcua, H., Cummings, J.L. Arch. Neurol. (2005) [Pubmed]
  33. Maturational changes in cerebral function in infants determined by 18FDG positron emission tomography. Chugani, H.T., Phelps, M.E. Science (1986) [Pubmed]
  34. Nuclear medicine. Alazraki, N.P. JAMA (1995) [Pubmed]
WikiGenes - Universities